Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase

被引:56
|
作者
Xiong, Yan [1 ,2 ]
Li, Fengling [3 ]
Babaultlt, Nicolas [1 ,2 ]
Dong, Aiping [3 ]
Zeng, Hong [3 ]
Wu, Hong [3 ]
Chen, Xin [1 ,2 ]
Arrowsmith, Cheryl H. [3 ,5 ,6 ]
Brown, Peter J. [3 ]
Liu, Jing [1 ,2 ]
Vedadi, Masoud [3 ,4 ]
Jin, Jian [1 ,2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA
[3] Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L7, Canada
[4] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada
[6] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
基金
加拿大创新基金会; 巴西圣保罗研究基金会; 英国惠康基金; 美国国家卫生研究院;
关键词
HISTONE METHYLTRANSFERASE; H3K9; METHYLATION; DNA METHYLATION; G9A; ESTABLISHMENT; CHROMATIN; TRANSCRIPTION; EUCHROMATIN; REFINEMENT; DISRUPTION;
D O I
10.1021/acs.jmedchem.6b01645
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
G9a-like protein (GLP) and G9a are highly homologous protein lysine methyltransferases (PKMTs) sharing approximately 80% sequence identity in their catalytic domains. GLP and G9a form a heterodimer complex and catalyze mono and dimethylation of histone H3 lysine 9 and nonhistone substrates. Although they are closely related, GLP and G9a possess distinct physiological and pathophysiological functions. Thus, GLP or G9a selective small-molecule inhibitors are useful tools to dissect their distinct biological functions. We previously reported potent and selective G9a/GLP dual inhibitors including UNC0638 and UNC0642. Here we report the discovery of potent and selective GLP inhibitors including 4 (MS0124) and 18 (MS012), which are >30-fold and 140-fold selective for GLP over G9a and other methyltransferases, respectively. The cocrystal structures of GLP and G9a in the complex with either 4 or 18 displayed virtually identical binding modes and interactions, highlighting the challenges in structure-based design of selective inhibitors for either enzyme.
引用
收藏
页码:1876 / 1891
页数:16
相关论文
共 50 条
  • [21] Epidithiodiketopiperazine as a pharmacophore for protein lysine methyltransferase G9a inhibitors: Reducing cytotoxicity by structural simplification
    Fujishiro, Shinya
    Dodo, Kosuke
    Iwasa, Eriko
    Teng, Yuou
    Sohtome, Yoshihiro
    Hamashima, Yoshitaka
    Ito, Akihiro
    Yoshida, Minoru
    Sodeoka, Mikiko
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (03) : 733 - 736
  • [22] Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a
    Poulard, Coralie
    Noureddine, Lara M.
    Pruvost, Ludivine
    Le Romancer, Muriel
    LIFE-BASEL, 2021, 11 (10):
  • [23] QM/MM MD and Free Energy Simulations of G9a-Like Protein (GLP) and Its Mutants: Understanding the Factors that Determine the Product Specificity
    Chu, Yuzhuo
    Yao, Jianzhuang
    Guo, Hong
    PLOS ONE, 2012, 7 (05):
  • [24] Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations
    Ji, Sen
    Ma, Shuang
    Wang, Wen-Jing
    Huang, Shen-Zhen
    Wang, Tian-qi
    Xiang, Rong
    Hu, Yi-Guo
    Chen, Qiang
    Li, Lin-Li
    Yang, Sheng-Yong
    CHEMICAL BIOLOGY & DRUG DESIGN, 2017, 89 (04) : 585 - 598
  • [25] Discovery of the First-in-Class G9a/GLP Covalent Inhibitors
    Park, Kwang-Su
    Xiong, Yan
    Yim, Hyerin
    Velez, Julia
    Babault, Nicolas
    Kumar, Prashasti
    Liu, Jing
    Jin, Jian
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, : 10506 - 10522
  • [26] Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
    Verma, Sharad K.
    Tian, Xinrong
    LaFrance, Louis V.
    Duquenne, Celine
    Suarez, Dominic P.
    Newlander, Kenneth A.
    Romeril, Stuart P.
    Burgess, Joelle L.
    Grant, Seth W.
    Brackley, James A.
    Graves, Alan P.
    Scherzer, Daryl A.
    Shu, Art
    Thompson, Christine
    Ott, Heidi M.
    Van Aller, Glenn S.
    Machutta, Carl A.
    Diaz, Elsie
    Jiang, Yong
    Johnson, Neil W.
    Knight, Steven D.
    Kruger, Ryan G.
    McCabe, Michael T.
    Dhanak, Dashyant
    Tummino, Peter J.
    Creasy, Caretha L.
    Miller, William H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (12): : 1091 - 1096
  • [27] Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure
    Milite, Ciro
    Feoli, Alessandra
    Horton, John R.
    Rescigno, Donatella
    Cipriano, Alessandra
    Pisapia, Vincenzo
    Viviano, Monica
    Pepe, Giacomo
    Amendola, Giorgio
    Novellino, Ettore
    Cosconati, Sandro
    Cheng, Xiaodong
    Castellano, Sabrina
    Sbardella, Gianluca
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (05) : 2666 - 2689
  • [28] Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor
    Shi, Yajie
    Zhang, Qiuyue
    Zhang, Maoying
    Chen, Yongsong
    Sun, Jianwen
    Chen, Lu
    Liu, Sen
    Liu, Zhongbo
    Yang, Jingyu
    Wu, Chunfu
    Zheng, Zhonghui
    Wang, Lihui
    Chen, Guoliang
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (08) : 5685 - 5702
  • [29] Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6
    Shen, Yudao
    Szewczyk, Magdalena M.
    Eram, Mohammad S.
    Smil, David
    Kaniskan, H. Umit
    de Freitas, Renato Ferreira
    Senisterra, Guillermo
    Li, Fengling
    Schapira, Matthieu
    Brown, Peter J.
    Arrowsmith, Cheryl H.
    Barsyte-Lovejoy, Dalia
    Liu, Jing
    Vedadi, Masoud
    Jin, Jian
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) : 9124 - 9139
  • [30] Discovery and Development of Potent CDK9-selective Inhibitors for Cancer Treatment
    Gao, Z.
    Sutton, J.
    Abrams, T.
    Faure, M.
    Yu, K.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 84 - 84